PNC Financial Services Group Inc. Has $2.64 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

PNC Financial Services Group Inc. grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 25.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,278 shares of the medical research company’s stock after acquiring an additional 2,916 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Charles River Laboratories International were worth $2,636,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of CRL. Versant Capital Management Inc raised its stake in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. raised its position in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Assetmark Inc. boosted its stake in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the period. ORG Wealth Partners LLC acquired a new stake in Charles River Laboratories International during the fourth quarter worth approximately $56,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Charles River Laboratories International during the 3rd quarter worth $59,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRL has been the topic of several analyst reports. Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Morgan Stanley reduced their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th. Finally, The Goldman Sachs Group decreased their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $198.36.

Charles River Laboratories International Trading Up 2.6 %

Shares of CRL stock opened at $171.27 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $274.77. The stock’s fifty day simple moving average is $167.74 and its 200 day simple moving average is $184.72. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $8.76 billion, a P/E ratio of 1,141.78, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.46 earnings per share. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In related news, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).